MX2016016384A - Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares. - Google Patents
Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares.Info
- Publication number
- MX2016016384A MX2016016384A MX2016016384A MX2016016384A MX2016016384A MX 2016016384 A MX2016016384 A MX 2016016384A MX 2016016384 A MX2016016384 A MX 2016016384A MX 2016016384 A MX2016016384 A MX 2016016384A MX 2016016384 A MX2016016384 A MX 2016016384A
- Authority
- MX
- Mexico
- Prior art keywords
- aggregates
- tau
- alzheimer
- relates
- agents
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 1
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000002600 positron emission tomography Methods 0.000 abstract 1
- 150000005255 pyrrolopyridines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de pirrolopiridina de fórmula (I) (ver Fórmula) o sus sales farmacéuticamente aceptables, que pueden ser adecuadas para la obtención de imágenes de agregados de tau, agregados de hojas b, agregados de beta-amiloide o agregados de alfa-sinucleína y, por tanto, son útiles en la unión y formación de imágenes de agregados de tau en pacientes de Alzheimer; más específicamente, esta invención se refiere a un método de utilización de los compuestos de esta invención como trazadores en las imágenes de tomografía por emisión de positrones (PET) para estudiar los depósitos de tau en el cerebro in vivo para permitir el diagnóstico de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas caracterizadas por patología tau; la invención se refiere además a un método para medir la eficacia clínica de agentes terapéuticos para la enfermedad de Alzheimer y otras enfermedades neurodegenerativas caracterizadas por patología tau.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/079834 WO2015188368A1 (en) | 2014-06-13 | 2014-06-13 | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
| PCT/US2015/034794 WO2015191506A2 (en) | 2014-06-13 | 2015-06-09 | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016016384A true MX2016016384A (es) | 2017-05-01 |
| MX375282B MX375282B (es) | 2025-03-06 |
Family
ID=54832744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016384A MX375282B (es) | 2014-06-13 | 2015-06-09 | Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9808542B2 (es) |
| EP (1) | EP3154970B1 (es) |
| JP (1) | JP6513107B2 (es) |
| KR (1) | KR102478430B1 (es) |
| CN (1) | CN106661018B (es) |
| AU (1) | AU2015274843B2 (es) |
| BR (1) | BR112016028345B1 (es) |
| CA (1) | CA2948528C (es) |
| DK (1) | DK3154970T3 (es) |
| ES (1) | ES2763095T3 (es) |
| HU (1) | HUE048395T2 (es) |
| MX (1) | MX375282B (es) |
| PL (1) | PL3154970T3 (es) |
| RU (1) | RU2695373C2 (es) |
| WO (2) | WO2015188368A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014097474A1 (ja) | 2012-12-21 | 2014-06-26 | 独立行政法人放射線医学総合研究所 | 脳内に蓄積したタウタンパク質をイメージングするための新規化合物 |
| SG11201811311VA (en) | 2016-07-22 | 2019-01-30 | Ac Immune Sa | Compounds for imaging tau protein aggregates |
| JP7059270B2 (ja) * | 2016-07-22 | 2022-04-25 | エーシー・イミューン・エス・アー | タウタンパク質凝集体を画像化するための化合物 |
| CN116473962A (zh) | 2017-06-02 | 2023-07-25 | 富士胶片富山化学株式会社 | 脑萎缩预防或治疗剂 |
| JPWO2018221728A1 (ja) | 2017-06-02 | 2020-04-02 | 富士フイルム富山化学株式会社 | アルツハイマー型認知症予防または治療剤 |
| JP7133547B2 (ja) | 2017-06-02 | 2022-09-08 | 富士フイルム富山化学株式会社 | 脊髄小脳変性症予防または治療剤 |
| CN110691595A (zh) | 2017-06-02 | 2020-01-14 | 富士胶片富山化学株式会社 | β-淀粉样蛋白量减少剂 |
| JP7370859B2 (ja) * | 2017-06-02 | 2023-10-30 | 富士フイルム富山化学株式会社 | タウオパチー予防または治療剤 |
| WO2019088083A1 (ja) | 2017-10-30 | 2019-05-09 | 富士フイルム富山化学株式会社 | エモパミル結合タンパク質結合剤およびその利用 |
| US11306089B2 (en) | 2018-01-24 | 2022-04-19 | Life Molecular Imaging Limited | Gamma-carboline compounds for the detection of Tau aggregates |
| US20210041447A1 (en) | 2018-01-24 | 2021-02-11 | Ac Immune Sa | Azacarboline compounds for the detection of tau aggregates |
| WO2019192533A1 (zh) * | 2018-04-04 | 2019-10-10 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
| KR102017324B1 (ko) | 2018-04-30 | 2019-09-02 | 경북대학교 산학협력단 | 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도 |
| JP7293343B2 (ja) * | 2018-05-09 | 2023-06-19 | アプリノイア セラピューティクス リミテッド | ヘテロアリール化合物及びその使用 |
| WO2019236884A1 (en) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| CN108676007B (zh) * | 2018-06-22 | 2020-06-26 | 厦门大学 | 放射性核素标记的苯并蝶啶类衍生物及其制备方法和应用 |
| CA3123215C (en) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with neuroprotective agents |
| WO2021097243A1 (en) | 2019-11-13 | 2021-05-20 | Aprinoia Therapeutics Inc. | Compounds for degrading tau protein aggregates and uses thereof |
| US20220008563A1 (en) * | 2020-07-10 | 2022-01-13 | The Regents Of The University Of California | Radiolabelled and nonradiolabelled pegylated compounds and uses thereof |
| US12036292B2 (en) * | 2020-08-06 | 2024-07-16 | Chdi Foundation, Inc. | Heterobiaryl compounds and imaging agents for imaging huntingtin protein |
| CN112939753B (zh) * | 2020-09-15 | 2022-04-05 | 浙江大学 | 一种1-茚酮类化合物的合成方法 |
| KR102240400B1 (ko) | 2020-11-19 | 2021-04-15 | 한국원자력연구원 | 베타-아밀로이드 검출용 수용성 화합물 |
| CN112745299B (zh) * | 2021-01-07 | 2022-01-25 | 温州大学 | 4-氰基-7,8-二氢异喹啉衍生物及其制备方法和应用 |
| TWI782769B (zh) * | 2021-10-28 | 2022-11-01 | 行政院原子能委員會核能研究所 | 一種新穎神經纖維糾結微管相關蛋白質Tau造影化合物、其製備方法及用途 |
| CN114149425A (zh) * | 2021-11-16 | 2022-03-08 | 上海应用技术大学 | 5-氟甲基吡啶衍生物和18-f同位素标记的5-氟甲基吡啶衍生物及其制备与应用 |
| CN114276259B (zh) * | 2022-01-04 | 2022-12-06 | 济川(上海)医学科技有限公司 | 一种马来酸二甲茚定关键中间体的制备方法 |
| CN115417816B (zh) * | 2022-09-05 | 2024-01-26 | 江苏南大光电材料股份有限公司 | 一种3,6-二溴-1-氯-异喹啉的制备方法 |
| WO2025230262A1 (ko) * | 2024-04-29 | 2025-11-06 | 심플렉스 주식회사 | 신규한 헤테로아릴 유도체 및 이의 aak1 억제 용도 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451566A (en) | 1993-11-17 | 1995-09-19 | Zeneca Limited | Herbicidal pyrrolopyridine compounds |
| JP5635727B2 (ja) | 2004-10-07 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法 |
| US20080027044A1 (en) | 2006-06-13 | 2008-01-31 | Kim Lewis | Prodrug antibiotic screens |
| WO2008103615A1 (en) | 2007-02-21 | 2008-08-28 | Kalypsys, Inc. | Isoquinolines useful as inducible nitric oxide synthase inhibitors |
| TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| AU2009260526A1 (en) | 2008-05-30 | 2009-12-23 | Merck Sharp & Dohme Corp. | Novel substituted indoles |
| WO2010129816A2 (en) | 2009-05-07 | 2010-11-11 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AU2012212323A1 (en) | 2011-02-01 | 2013-09-12 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| US8684313B2 (en) | 2011-02-02 | 2014-04-01 | Ocean Rodeo Sports Inc. | Inflatable kite with leading edge swept forwards at wingtip |
| WO2013040183A1 (en) * | 2011-09-16 | 2013-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof |
| US20150336948A1 (en) * | 2012-05-29 | 2015-11-26 | Merck Sharp & Dohme Corp. | Isotopically Labeled Biaryl Urea Compounds |
| CN103450152B (zh) * | 2012-06-04 | 2015-11-18 | 济南海乐医药技术开发有限公司 | 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物 |
| GB201304526D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201404498D0 (en) * | 2014-03-13 | 2014-04-30 | Proximagen Ltd | New compounds |
-
2014
- 2014-06-13 WO PCT/CN2014/079834 patent/WO2015188368A1/en not_active Ceased
-
2015
- 2015-06-09 KR KR1020177000709A patent/KR102478430B1/ko active Active
- 2015-06-09 AU AU2015274843A patent/AU2015274843B2/en active Active
- 2015-06-09 BR BR112016028345-7A patent/BR112016028345B1/pt active IP Right Grant
- 2015-06-09 CA CA2948528A patent/CA2948528C/en active Active
- 2015-06-09 DK DK15806980.7T patent/DK3154970T3/da active
- 2015-06-09 WO PCT/US2015/034794 patent/WO2015191506A2/en not_active Ceased
- 2015-06-09 EP EP15806980.7A patent/EP3154970B1/en active Active
- 2015-06-09 ES ES15806980T patent/ES2763095T3/es active Active
- 2015-06-09 PL PL15806980T patent/PL3154970T3/pl unknown
- 2015-06-09 US US15/317,333 patent/US9808542B2/en active Active
- 2015-06-09 CN CN201580031335.2A patent/CN106661018B/zh active Active
- 2015-06-09 JP JP2016572520A patent/JP6513107B2/ja active Active
- 2015-06-09 HU HUE15806980A patent/HUE048395T2/hu unknown
- 2015-06-09 MX MX2016016384A patent/MX375282B/es active IP Right Grant
- 2015-06-09 RU RU2016150404A patent/RU2695373C2/ru active
-
2017
- 2017-10-04 US US15/724,402 patent/US10022461B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3154970T3 (da) | 2020-01-20 |
| AU2015274843A1 (en) | 2016-11-10 |
| RU2016150404A3 (es) | 2018-11-30 |
| MX375282B (es) | 2025-03-06 |
| EP3154970A4 (en) | 2017-11-15 |
| US10022461B2 (en) | 2018-07-17 |
| AU2015274843B2 (en) | 2018-11-22 |
| EP3154970B1 (en) | 2019-11-06 |
| PL3154970T3 (pl) | 2020-04-30 |
| ES2763095T3 (es) | 2020-05-27 |
| CN106661018A (zh) | 2017-05-10 |
| US9808542B2 (en) | 2017-11-07 |
| RU2016150404A (ru) | 2018-07-18 |
| CA2948528C (en) | 2022-05-31 |
| US20170119912A1 (en) | 2017-05-04 |
| KR102478430B1 (ko) | 2022-12-15 |
| WO2015188368A1 (en) | 2015-12-17 |
| RU2695373C2 (ru) | 2019-07-23 |
| WO2015191506A3 (en) | 2016-02-04 |
| US20180071412A1 (en) | 2018-03-15 |
| WO2015191506A2 (en) | 2015-12-17 |
| BR112016028345B1 (pt) | 2022-11-29 |
| JP6513107B2 (ja) | 2019-05-15 |
| RU2019115483A (ru) | 2019-06-13 |
| BR112016028345A2 (pt) | 2017-08-22 |
| CA2948528A1 (en) | 2015-12-17 |
| EP3154970A2 (en) | 2017-04-19 |
| BR112016028345A8 (pt) | 2021-06-29 |
| JP2017521387A (ja) | 2017-08-03 |
| HUE048395T2 (hu) | 2020-08-28 |
| CN106661018B (zh) | 2019-07-19 |
| KR20170016481A (ko) | 2017-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016016384A (es) | Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares. | |
| ECSP088645A (es) | Nuevos benzotiazoles sustituidos con heteroaril | |
| IL290693A (en) | Neuromelanin-sensitive mri for assessing parkinson's disease | |
| BR112015025140A2 (pt) | 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem | |
| ECSP13012609A (es) | Composición farmacéutica | |
| CL2020001097A1 (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| MX2014003357A (es) | Terapia basada en proteina y diagnostico de patalogia mediada por tau en la enfermedad de alzheimer. | |
| CO7131359A2 (es) | Agentes de imagen para detectar disfunción neurológica | |
| MX379043B (es) | Uso de sobetirome en el tratamiento de enfermedades de mielinización. | |
| UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| BR112014012822A2 (pt) | radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2 | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| MX2016008624A (es) | Inhibidores de serina/treonina cinasa. | |
| AR114029A2 (es) | Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos | |
| HUE063369T2 (hu) | Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben | |
| MX392523B (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar | |
| EP3088898A4 (en) | Method for diagnosis of alzheimer's disease and frontotemporal lobar degeneration, diagnostic agent, therapeutic agent, and screening method for said agents | |
| ECSP19043790A (es) | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de PDE1 | |
| CO6592030A2 (es) | Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa | |
| ECSP099641A (es) | Nuevos benzotiofenos y benzofuranos sustituidos en la posición 2 con heteroarilo 709 | |
| AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
| BR112015027015A2 (pt) | derivados de 2-fenil ou 2-hetaril imidazol[1,2-a]piridina | |
| MX386900B (es) | Compuestos para formacion de imagenes de agregados de proteinas tau. | |
| PL3449009T3 (pl) | Biomarkery mikroRNA we krwi do diagnozowania choroby Alzheimera | |
| WO2010051196A8 (en) | Novel substituted azabenzoxazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |